Current treatments for renal failure due to multiple myeloma

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

(2012) R. Vij et al.   BLOOD

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

(2012) L. Rosinol et al.   BLOOD

Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases

(2012) N. Leung et al.   Clinical Journal of the American Society of Nephrology

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

(2012) M A Dimopoulos et al.   LEUKEMIA

Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis

(2012) C. A. Hutchison et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function

(2011) M. A. Dimopoulos et al.   ANNALS OF ONCOLOGY

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

(2011) P. Moreau et al.   BLOOD

Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney

(2011) C. A. Hutchison et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The pathogenesis and diagnosis of acute kidney injury in multiple myeloma

(2011) Colin A. Hutchison et al.   Nature Reviews Nephrology

Renal Improvement in Myeloma with Bortezomib plus Plasma Exchange

(2011) Brian L. Burnette et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Follow-Up of Recipients of Combined Human Leukocyte Antigen-Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With End-Stage Renal Disease

(2011) Thomas R. Spitzer et al.   TRANSPLANTATION

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

(2010) Ulrike Klein et al.   ANNALS OF HEMATOLOGY

Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency

(2010) Patrizia Tosi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Immunoglobulin light chains activate nuclear factor- B in renal epithelial cells through a Src-dependent mechanism

(2010) W.-Z. Ying et al.   BLOOD

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

(2010) Meletios Dimopoulos et al.   CANCER

Meeting the Unmet Needs in Anticoagulant Therapy

(2010)   EUROPEAN JOURNAL OF HAEMATOLOGY

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study

(2010) Javier De La Rubia et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

(2010) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

(2010) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

(2010) Maria Roussou et al.   LEUKEMIA RESEARCH

Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma

(2009) Gaurav C. Parikh et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis

(2009) C. A. Hutchison et al.   Clinical Journal of the American Society of Nephrology

Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA

(2009) Fortunato Morabito et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study

(2009) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA

Outcome definitions in non-dialysis intervention and prevention trials in acute kidney injury (AKI)

(2009) Z. H. Endre et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study

(2009) D. J. Tsakiris et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Acute Kidney Injury: Definitions and New Paradigms

(2008) Zoltán H. Endre   ADVANCES IN CHRONIC KIDNEY DISEASE

Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease?

(2008) Colin A Hutchison et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Bortezomib-Induced Survival Signals and Genes in Human Proximal Tubular Cells

(2008) R. Sarkozi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

(2008) J F San-Miguel et al.   LEUKEMIA

Pathogenesis and treatment of renal failure in multiple myeloma

(2008) M A Dimopoulos et al.   LEUKEMIA

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

(2008) Maria Roussou et al.   LEUKEMIA & LYMPHOMA

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure

(2008) Colin A Hutchison et al.   BMC Nephrology